Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Merck KGaA Add to portfolio

DAXX:MRK, Jan 21, 04:49 UTC

Latest DAXX:MRK News

Filter your feed

Apply Filter

Wednesday, January 16


News

Merck or AbbVie: Which Company Returns More Value to Shareholders?

MRK ABBV

Merck & Co. or AbbVie: Which Is Performing Better This Month?(Continued from Prior Part)Value returned to shareholders On its third-quarter earnings conference call, Merck & Co. (MRK) announced a 15% increase in its quarterly dividend to.

Read Full Details

Topics:
  • Business
  • Financial
News

Crawford Investment Counsel INC Has Upped Its Stake in Merck & Co INC (MRK) by $3.02 Million

MRK MRK

1.87 billion shares or 0.48% less from 1.88 billion shares in 2018Q2 were reported. Crawford Investment Counsel Inc who had been investing in Merck & Co Inc for a number of months, seems to be bullish on the $193.73 billion market cap company. Crawford Investment Counsel Inc, which manages about $4.53B and $3.08 billion US Long portfolio, decreased its stake in New York Cmnty Bancorp Inc (NYSE:NYCB) by 841,567 shares to 46,162 shares, valued at $595,000 in 2018Q3, according to the filing. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: Streetinsider.com and their article: “Merck’s (MRK) KEYTRUDA Reduced Risk of Death by 31% Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma – StreetInsider.com” published on January 14, 2019 as well as Investorplace.com‘s news article titled: “3 Big Stock Charts for Tuesday: Broadcom, Facebook and Merck – Investorplace.com” with publication date: January 15, 2019.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, January 15


News

Merck or AbbVie: Which Has the Better Cost Structure?

MRK ABBV

Merck & Co. or AbbVie: Which Is Performing Better This Month? In its third-quarter earnings conference presentation, Merck & Co. (MRK) said that it expects its operating expenses to rise YoY (year-over-year) in the low to mid-single digits in 2018, mainly driven by increased R&D (research and development) expenses. The company also expects its GAAP (generally accepted accounting principles) effective tax rate to be in the range of 26.0%–27.0%.

Read Full Details

Topics:
  • Business
  • Financial
News

Merck or AbbVie: Which Has More Robust Margins?

MRK ABBV

Merck & Co. or AbbVie: Which Is Performing Better This Month? On its third-quarter earnings conference call, Merck & Co. (MRK) forecast an expansion in its operating margin in the coming years, mainly driven by growth in its oncology business, a favorable product mix, and rapid revenue growth. The company also expects its effective tax rate for 2018 to fall in the range of 19%–20%. In its third-quarter earnings conference presentation, it also forecast a 1% YoY contraction in its product gross margin for 2018.

Read Full Details

Topics:
  • Business
  • Financial
News

Merck or AbbVie: Which Has a Stronger Earnings Trajectory?

MRK

During its third-quarter earnings conference presentation, Merck & Co. (MRK) announced a change in its non-GAAP (generally accepted accounting principles) EPS forecast range for 2018 from $4.22–$4.30 to $4.30–$4.36. The midpoint of its forecast EPS range increased from $4.26 to $4.33.

Read Full Details

Topics:
  • Business
  • Politics
  • Financial
News

3 Big Stock Charts for Tuesday: Broadcom, Facebook and Merck

MRK FB +1 more MRK FB AVGO

Investors started the new trading week in the same lethargic mood they left the old one … not bearish so much as disinterested until they have more clarity. The S&P 500’s close of 2,858.61 was 0.53% lower than Friday’s close, leaving the market as much within reach of a renewed rally as it is on the verge of a correction. The stock charts of Facebook (NASDAQ:FB), Merck (NYSE:MRK) and Broadcom (NASDAQ:AVGO) have been quietly moving into grooves that have largely been overlooked, leaving each on the cusp of trade-worthy moves. The stock is back in rally mode though, and the next test of that very same technical ceiling is even better founded effort than the previous one was.

Read Full Details

Topics:
  • Business
  • Financial

Monday, January 14


News

Merck or AbbVie: Which Has the More Robust Revenue Trajectory?

MRK ABBV

Merck & Co. or AbbVie: Which Is Performing Better This Month? (Continued from Prior Part)## Revenue guidanceDuring its third-quarter earnings conference presentation, Merck & Co. (MRK) announced a change in its 2018 revenue forecast range from $42.0 billion–$42.8 billion to $42.1 billion–$42.7 billion. Additionally, according to the company’s third-quarter earnings conference call, it also expects a small impact on its 2018 revenue attributable to foreign exchange at mid-October rates.During its 37th Annual J.P. Morgan Healthcare Brokers Conference presentation, AbbVie (ABBV) projected its net revenue for 2018 to be $32.7 billion, YoY operational growth of 15%. According to the company’s third-quarter earnings conference call, it expects a favorable revenue impact of lower than 1% due to foreign currency fluctuations in 2018.## ## Wall Street estimatesWall Street analysts expect Merck’s revenues to be $42.31 billion, $44.53 billion, and $46.98 billion, respectively, in 2018, 2019, and 2020, implying YoY revenue rises of 5.45%, 5.25%, and 5.50%.On the other hand, Wall Street analysts expect AbbVie’s revenues to be $32.79 billion, $33.60 billion, and $35.64 billion, respectively, in 2018, 2019, and 2020, implying YoY revenue rises of 16.20%, 2.48%, and 6.08%.Merck & Co. is expected to report a gradual rise in revenue from 2018 to 2020, while AbbVie is expected to report a more volatile revenue growth trajectory in the same timeframe.In the next article, we’ll compare the earnings growth prospects of Merck & Co. and AbbVie in greater detail.Continue to Next PartBrowse this series on Market Realist: * Part 1 - Analysts’ Recommendations for Merck & Co. in January * Part 2 - Analysts’ Recommendations for AbbVie in January * Part 4 - Merck or AbbVie: Which Has a Stronger Earnings Trajectory?

Read Full Details

Topics:
  • Business
  • Financial
News

What's in Store for Merck in 2019 After a Solid Run in '18?

MRK

After a solid run in 2018, supported by strong quarterly results and positive pipeline and regulatory updates, Merck & Co., Inc. MRK looks well poised to continue the momentum in 2019. A significant part of Merck’s outperformance this year was driven by strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda. Merck also gained several label expansion approvals for Keytruda and another cancer drug Lynparza, which it markets in partnership with AstraZeneca AZN. For Keytruda, a key FDA approval in October was the label expansion as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC) — a difficult-to-treat lung cancer patient population — based on data from the phase III KEYNOTE-407 study. In December, Merck announced plans to acquire privately held animal health technology provider Antelliq Group from BC Partners. What to Expect in 2019? For Keytruda, several regulatory decisions for new indications in the United States as well as in Europe are due in 2019, which if approved can further boost sales.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Sunday, January 13


News

Here's Why Merck & Co. Surged 35.8% in 2018

MRK

Shares of Merck & Co.(NYSE: MRK), a big pharmaceutical company, climbed 35.8% in 2018, according to data from S&P Global Market Intelligence. Merck's shares began 2018 from a low point after the company made investors nervous by pulling a European application for its PD-1 checkpoint inhibitor, Keytruda, in late 2017. Merck outperformed its big pharma peers by a mile last year because nearly all U.S. patients diagnosed with NSCLC will receive Keytruda on its own or in combination with standard chemotherapy going forward. Now what. As a standard first treatment for most lung cancer patients, sales of Merck's blockbuster could grow from $5 billion during the first nine months of 2018 to $15 billion annually by 2024.

Read Full Details

Topics:
  • Business
  • Health

Friday, January 11


News

China Recombinant Human Follitropin Market Report 2018-2022 Featuring Merck Serono (GONAL-f) & GeneScience Pharmaceuticals Co., Ltd. (Jinsaiheng)

MRK

According to the researcher, the FSH products in China include Urofollitropin (u-FSH) extracted from urine and Recombinant Human Follitropin (rh-FSH). In China, Recombinant Human Follitropin has been approved (1) to treat anovulation (including polycystic ovary syndrome, PCOS) that cannot be cured by Clomiphene Citrate; and (2) to be used for superovulation and follicular development by assisted reproductive treatment such as in vitro fertilization-embryo transfer (IVF-ET), gamete intrafallopian transfer (GIFT), and intracytoplasmic sperm injection (ICSI). Meanwhile, as the average childbearing age of Chinese women continues to rise and China's family planning policy is loosened, many older women plan to have a second child, which will drive the demand for Recombinant Human Follitropin in China. 3 Analysis of Major Manufacturers of Recombinant Human Follitropin in China, 2013-20173.1 Analysis on Market Share of Major Manufacturers of Recombinant Human Follitropin3.1.1 Market Share by Sales Value3.1.2 Market Share by Sales Volume3.2 Merck Serono3.2.1 Profile of Merck Serono3.2.2 Sales of Merck Serono's Recombinant Human Follitropin in China3.3 GeneScience Pharmaceuticals Co., Ltd. 3.3.1 Profile of GeneScience Pharmaceuticals Co., Ltd. 3.3.2 Sales of GeneScience Pharmaceuticals Co., Ltd.'s Recombinant Human Follitropin in China.

Read Full Details

Topics:
  • Business
  • Health
  • Financial